P R E S S R E L E A S E
LINEBERRY RESEARCH ASSOCIATES ANNOUNCES STAFF APPOINTMENTS
Research Triangle Park, NC, March 22, 1996 -- Lineberry Research Associates (LRA), a pharmaceutical research and consulting firm borne out of the Glaxo Wellcome merger, today announced the appointment of several new staff members: Martha M. Abou-Donia, Ph.D., as Director of Clinical Research, J. Neal Weakly, Ph.D., as Senior Scientific Advisor, Moise Khayrallah, Ph.D., as Senior Clinical Research Scientist, Kimberly Hines, as Clinical Research Scientist, and Dawn Talley, as Office Manager.
"These highly respected individuals are valuable additions to the LRA family," said Charles G. Lineberry, Ph.D., President of LRA. "These appointments, coupled with the expansion and diversity of our client roster, are evidence of LRAs dramatic growth in our first year of operation."
Dr. Abou-Donia brings 27 years of research experience to the LRA team. Prior to joining LRA, Dr. Abou-Donia worked at Burroughs Wellcome Co. in the Medical Division, where she served as Project Leader for several successful development programs that resulted in marketed compounds, including Nimbex® (cisatracurium besylate), a neuromuscular blocker for surgical relaxation. In addition, she has had extensive experience in the planning and execution of both domestic and international clinical development programs.
With 27 years of experience in biomedical research and clinical drug development, Dr. Weakly has extensive knowledge of the development of compounds in CNS, anesthesia and critical care. Before joining LRA, he served as Associate Director of Neurology/Psychiatry at Burroughs Wellcome Co., where he directed the submission of numerous INDs and NDAs, resulting in three approved compounds through the Pilot Division of the U.S. Food and Drug Administration.
Dr. Khayrallah joined LRA after six years at Burroughs Wellcome Co., where he was the international project leader for clinical trials in smoking cessation. He brings to LRA a strong background in clinical research and project management as well as statistical strategy and analysis.
Before joining LRA, Ms. Hines worked for Burroughs Wellcome Co. for five years, where she had project management responsibilities for a 40- center international pivotal efficacy and safety trial in pediatric epilepsy patients. Ms. Hines will provide scientific report writing services in her new position at LRA, as well as clinical trial management.
Ms. Talley comes to LRA after five years at Burroughs Wellcome Co., where she provided administrative support in the Psychiatry Department. As office manager at LRA, she will provide complete office management services, including project management and financial tracking.
"The breadth and depth of LRAs experience and capability are best showcased in our people," added Cathy Frieden Lineberry, Vice President, Marketing and Business Development. "LRA is unique in that we offer our clients an experienced team of drug development experts with proven track records of success in pharmaceutical research, development and marketing."
Lineberry Research Associates is a full-service contract research organization that provides complete development capabilities, from IND application to NDA approval and post-marketing, with particular expertise in CNS, anesthesia and analgesia. In addition to managing clinical trials, LRA differentiates itself by providing its pharmaceutical and biotechnology clients with high level scientific and regulatory consulting services and proven expertise in scientific writing and communications.